BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21922524)

  • 21. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
    Cerci JJ; Györke T; Fanti S; Paez D; Meneghetti JC; Redondo F; Celli M; Auewarakul C; Rangarajan V; Gujral S; Gorospe C; Campo MV; Chung JK; Morris TP; Dondi M; Carr R;
    J Nucl Med; 2014 Oct; 55(10):1591-7. PubMed ID: 25214642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
    Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
    Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.
    Alavi A; Shrikanthan S; Aydin A; Talanow R; Schuster S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):261-6. PubMed ID: 21658653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
    Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
    Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.
    Kahn ST; Flowers C; Lechowicz MJ; Hollenbach K; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):961-5. PubMed ID: 17145526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
    Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):810-3. PubMed ID: 23384899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.
    Filmont JE; Gisselbrecht C; Cuenca X; Deville L; Ertault M; Brice P; De Kerviler E; Briere J; Larghero J; Moretti JL; Mounier N
    Cancer; 2007 Sep; 110(6):1361-9. PubMed ID: 17623832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
    Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
    Tateishi U; Tatsumi M; Terauchi T; Ishizawa K; Ogura M; Tobinai K
    Cancer Sci; 2011 Feb; 102(2):414-8. PubMed ID: 21156007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography scanning in the assessment of patients with lymphoma.
    Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
    Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
    Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
    Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma.
    Schot BW; Pruim J; van Imhoff GW; Sluiter WJ; Vaalburg W; Vellenga E
    Haematologica; 2006 Apr; 91(4):490-5. PubMed ID: 16533726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.